Riskpilot← Back to searchSign inGet full accessScandilaser AB
ABActiveOrg 5567438048Smedjegatan 11Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20070 employees
Revenue 2024
SEK 3K
-6% vs 2023
EBITDA margin
-19839.4%
+33% vs 2023
Equity ratio
97.8%
Financial strength
Net profit 2024
SEK -570K
+39% vs 2023
| Revenue | SEK 3K | -6% |
| EBITDA | SEK -595K | +33% |
| Net profit | SEK -570K | +39% |
| Total assets | SEK 1M | -36% |
| Equity | SEK 981K | -37% |
| Employees | 0 | — |
Legal name
Scandilaser AB
Org number
5567438048
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
22 november 2007
Share capital
SEK 100 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget har till föremål för sin verksamhet att bedriva handel med medicinsk teknisk utrustning, bedriva handel med värdepapper samt bedriva därmed förenlig verksamhet.
Address
Smedjegatan 11
Email
tclund2@yahoo.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 3 | 3 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −790 | −784 | −1 102 | −891 | −595 |
| Depreciation & amort. | −101 | −101 | −101 | −78 | — |
| EBIT | −891 | −885 | −1 203 | −970 | −595 |
| Net financials | 90 | 60 | 43 | 43 | 25 |
| Profit before tax | −800 | −825 | −1 161 | −927 | −570 |
| Tax | −0 | −0 | — | — | — |
| Net profit | −800 | −825 | −1 161 | −927 | −570 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 4 479 | 3 653 | 2 493 | 1 561 | 1 003 |
| Equity | 4 464 | 3 638 | 2 478 | 1 551 | 981 |
| Long-term debt | 0 | 0 | — | — | — |
| Short-term debt | 15 | 15 | 15 | 10 | 22 |
| Total debt | 15 | 15 | 15 | 10 | 22 |
EBITDA margin
-19839.4%
This company
15.8%
Market median
-125666% vs market
20202024
Equity ratio
97.8%
This company
38.2%
Market median
+156% vs market
20202024
Return on equity
-58.1%
This company
18.4%
Market median
-416% vs market
20202024
Net profit margin
-18996.4%
This company
8.1%
Market median
-234623% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.02×
This company
0.62×
Market median
+97% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
TC Chief Executive Officer | Chief Executive Officer | 2020 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2020 | |
| Former (1) | ||
| Deputy Board Member | 2020 – 2020 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Scandilaser AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Tor Charles Lund | Chief Executive Officer | 0 companies |
| Mats Elon Bäckman | Deputy Board Member | 0 companies |
| Ingrid Elisabeth Kärmander Lund | Deputy Board Member | 0 companies |